HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, and chronic diseases, announced that Dr. Richard Law has joined as Chief Business Officer. With more than two decades of experience in drug discovery and business development, Dr. Law brings tremendous expertise in creating biopharma partnerships, shepherding company growth, and securing life sciences funding.
“In recent months, HAYA has reached significant milestones with our regulatory genome RNA-guided platform, including the announcement of our collaboration with Eli Lilly and Company,” said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. “As we continue our rapid growth and expansion into new disease areas, Richard’s unparalleled expertise in investments and collaboration strategies at the intersection of biology and technology, in addition to company building, will help us form innovative partnerships and accelerate a broader reach for our programmable, disease-modifying therapeutics.”
